These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 34726751)

  • 1. Single-Dose Ad26.COV2.S Vaccine-Room for Improvement.
    Tehrani ZR; Sajadi MM
    JAMA Netw Open; 2021 Nov; 4(11):e2133012. PubMed ID: 34726751
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
    Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
    Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies.
    Tada T; Zhou H; Samanovic MI; Dcosta BM; Cornelius A; Herati RS; Mulligan MJ; Landau NR
    Front Immunol; 2022; 13():797589. PubMed ID: 35350781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.
    Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L
    Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Schmitz KS; Geers D; Bogers S; van Haren E; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Akkerman R; Beukema M; Lafeber M; van Baarle D; de Vries RD; van der Kuy PHM; GeurtsvanKessel CH;
    Clin Infect Dis; 2023 Feb; 76(3):e533-e536. PubMed ID: 35723273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
    Naranbhai V; Garcia-Beltran WF; Chang CC; Berrios Mairena C; Thierauf JC; Kirkpatrick G; Onozato ML; Cheng J; St Denis KJ; Lam EC; Kaseke C; Tano-Menka R; Yang D; Pavlovic M; Yang W; Kui A; Miller TE; Astudillo MG; Cahill JE; Dighe AS; Gregory DJ; Poznansky MC; Gaiha GD; Balazs AB; Iafrate AJ
    J Infect Dis; 2022 Apr; 225(7):1141-1150. PubMed ID: 34888672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Induced Immune Thrombotic Thrombocytopenia with Concurrent Arterial and Venous Thrombi Following Ad26.COV2.S Vaccination.
    Charidimou A; Samudrala S; Cervantes-Arslanian AM; Sloan JM; Dasenbrock HH; Daneshmand A
    J Stroke Cerebrovasc Dis; 2021 Dec; 30(12):106113. PubMed ID: 34547677
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
    Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Massive bullous local reaction following administration of Ad26.COV2.S COVID-19 vaccine.
    Montero-Menárguez J; Falkenhain-López D; Guzmán-Pérez LM; Rodríguez-Peralto JL; Tous-Romero F; Gallego-Álvarez S
    Int J Dermatol; 2022 May; 61(5):636-638. PubMed ID: 35049059
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19.
    Corchado-Garcia J; Zemmour D; Hughes T; Bandi H; Cristea-Platon T; Lenehan P; Pawlowski C; Bade S; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Wagner T; Soundararajan V
    JAMA Netw Open; 2021 Nov; 4(11):e2132540. PubMed ID: 34726743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome.
    Li HF; Hu SM; Lv M
    JAMA; 2022 Jan; 327(4):392-393. PubMed ID: 35076675
    [No Abstract]   [Full Text] [Related]  

  • 14. Presumptive Guillain-Barré Syndrome Associated With Receipt of the Ad26.COV2.2.S COVID-19 Vaccine-Reply.
    Woo EJ; Dimova RB; Mba-Jonas A
    JAMA; 2022 Jan; 327(4):393-394. PubMed ID: 35076672
    [No Abstract]   [Full Text] [Related]  

  • 15. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
    Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
    JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study.
    Hyun H; Choi MJ; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
    J Korean Med Sci; 2022 Jul; 37(27):e210. PubMed ID: 35818701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.
    Ukey R; Bruiners N; Mishra H; Mishra PK; McCloskey D; Onyuka A; Chen F; Pinter A; Weiskopf D; Sette A; Roy J; Gaur S; Gennaro ML
    BMC Med; 2022 Jan; 20(1):32. PubMed ID: 35073931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced immunity after Ad26.COV2.S vaccine breakthrough infection.
    Montefiori DC
    Cell Rep Med; 2022 Mar; 3(3):100579. PubMed ID: 35474738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the "Green Pass" Policy.
    Polvere I; Parrella A; Zerillo L; Voccola S; Cardinale G; D'Andrea S; Madera JR; Stilo R; Vito P; Zotti T
    Front Immunol; 2022; 13():833085. PubMed ID: 35634315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.